JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Somatic JAK-2 V617F Mutational Analysis in Polycythemia Rubra Vera: a Tertiary Care Center Experience
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Somatic JAK-2 V617F Mutational Analysis in Polycythemia Rubra Vera: a Tertiary Care Center Experience
Sultan, Sadia; Irfan, Syed Mohammed; Khan, Sadia Rashid;
  PDF(new window)
 Abstract
Background: Polycythemia rubra vera (PV), being a primary polycythemia, is caused by neoplastic proliferation of erythroid, megakaryocytic and granulocytic lineages which result in panmyelosis. PV patients have a somatic acquired mutation in the Janus kinase (JAK2) pathway, rendering cell proliferation independent of the normal regulatory mechanisms that regulate erythropoiesis. The rational of this study was to determine the prevalence of the JAK-2 V617F mutation in Pakistani patients with PV. Materials and Methods: In this cross sectional study, 26 patients with PV were enrolled from January 2010 to December 2014. Patients were diagnosed based on WHO criteria for PV. All were screened for G-T point mutation (V617F) in the JAK2 gene on chromosome 9 by an allele specific PCR. Results: The mean age was (range 36-72) and the male to female ratio was 2:1. The frequency of JAK2 V617F positivity in our PV patients was found to be 92.3%. Overall 30.7% of patients were asymptomatic and remaining 69.3% presented with symptomatic disease. The mean hemoglobin was with the mean hematocrit of . The mean total leukocyte count was and the platelet count was . A positive correlation of JAK2 V617F mutation was established with high TLC count (P
 Keywords
JAK-2 V617F;polycythaemia rubra vera;erythrocytosis;Pakistan;
 Language
English
 Cited by
1.
Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms,;;;;;;;;

Asian Pacific Journal of Cancer Prevention, 2016. vol.17. 10, pp.4647-4653 crossref(new window)
 References
1.
Agarwal MB, Malhotra H, Chakrabarti P, et al (2015). Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythaemia vera, and essential thrombocythemia. Indian J Med Paediatr Oncol, 36, 3-16. crossref(new window)

2.
Al-Thwani AN, Yaseen NY, Khaleel KJ (2010). The Role of JAK2 Mutation in Polycythaemia Vera in Some Iraqi Patients. Iraqi J Cancer Med Genetics, 43, 42-5.

3.
Baxter EJ, Scott LM, Campbell PJ, et al (2005). Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 1054-61. crossref(new window)

4.
Duangnapasatit B, Rattarittamrong E, Rattanathammethee T, et al (2015). Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Asian Pac J Cancer Prev, 16, 5013-8. crossref(new window)

5.
Duletic AN, Dekanic A, Hadzisejdic I, et al (2012). JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms. Coll Antropol, 36, 859-65.

6.
Hamidah NH, Farisah NR, Azlinda AB, et al (2012). A study of JAK2 (V617F) gene mutation in patients with chronic myeloproliferative disorders. Clin Ter, 163, 109-13.

7.
James C, Ugo V, Le Couedic JP, et al (2005). A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 1144-8 crossref(new window)

8.
Karkucak M, Yakut T, Ozkocaman V, et al (2012). Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera. Mol Biol Rep, 39, 8663-7. crossref(new window)

9.
Kiladjian JJ (2012). The spectrum of JAK2-positive myeloproliferative neoplasms. Hematol Am Soc Hematol Educ Program, 2012, 561-6.

10.
Khattak SA, Ahmed S, Anwar J, Bozdar M (2012). Frequency of Janus associated kinase 2 (V617F) mutation in patients of polycythemia vera. J Coll Physicians Surg Pak, 22, 80-3.

11.
Lieu C, Wu H, Hon HS, et al (2008). Prevalence of the JAK2 V617F mutation in Taiwanese patients with chronic myeloproliferative disorders. Int Med J, 111, 145-9.

12.
Ma X, Vanasse G, Cartmel B, Wang Y, Selinger HA (2008). Prevalence of polycythaemia vera and essential thrombocythemia. Am J Hematol, 83, 359-62. crossref(new window)

13.
Payzin KB, Savasoglu K, Alacacioglu I, et al (2014). JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk, 14, 525-33. crossref(new window)

14.
Ren Y, Fu R, Qu W, et al (2015).Clinical analysis of 70 cases of polycythemia vera. Zhonghua Yi Xue Za Zhi, 95, 1378-81.

15.
Sag SO, Gorukmez O, Ture M, et al (2015). MMP2 gene-735 C/T and MMP9 gene -1562 C/T polymorphisms in JAK2V617F positive myeloproliferative disorders. Asian Pac J Cancer Prev, 16, 443-9. crossref(new window)

16.
Sazawal S, Bajaj J, Chikkara S, et al (2010). Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders. Indian J Med Re, 132, 423-7.

17.
Sadiq MA, Ahmed S, Ali N (2013). Frequency of Janus associated kinase 2 (JAK2) mutation in patients of BCR-ABL negative myeloproliferative neoplasms. Applied Life Sciences, 2, 235-40.

18.
Tefferi A, Barbui T (2015). Polycythaemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol, 90, 162-73. crossref(new window)

19.
Thiele J, Kvasnicka HM, Orazi A, et al. Polycythaemia vera. In: Swerdlow HS, Campo E, Haris LN, et al (2008). WHO classification of tumours of haemopoietic and lymphoid tissues. Lyon: International agency for research on cancer, 40.

20.
Yang JJ, Chen H, Zheng XQ, et al (2015). Methylated alteration of SHP1 complements mutation of JAK2 tyrosine kinase in patients with myeloproliferative neoplasm. Asian Pac J Cancer Prev, 16, 2219-25. crossref(new window)

21.
Yonal-Hindilerden I, Daglar-Aday A, Akadam-Teker B, et al (2015). The durden of JAK2V617F mutated allele in Turkish patients with myeloproliferative neoplasms. J Clin Med Res, 7, 161-70. crossref(new window)

22.
Zhang ZR, Duan YC (2014). Interferon apha 2b for treating patients with JAK2V617F positive polycythaemia vera and essential thrombocytosis. Asian Pac J Cancer Prev, 15, 1681-4. crossref(new window)

23.
Zhu JF, Liu Y, Liu P, et al (2011). JAK2V617F mutation in the patients with myeloproliferative disorder and its relation with clinical characteristics. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 19, 916-20.